Jun 28, 2026
16 MIN READ

Ozempic and Heart Palpitations: Causes and What to Do

Heart palpitations during semaglutide treatment are a real concern for some patients. Understanding the mechanisms behind this side effect and knowing when to contact your provider can help you manage your weight loss therapy safely.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 28, 2026
16 MIN READ

ozempic and heart palpitations: causes and what to do — PlexusDx GLP-1 education

Last reviewed: June 29, 2026

Last updated: June 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has helped millions lose weight, but some patients report heart palpitations—an uncomfortable awareness of their heartbeat that can feel like racing, skipping, or pounding. Clinical data shows cardiovascular side effects occur in a small percentage of users, yet they deserve careful attention. PlexusDx provides personalized semaglutide therapy informed by genetic insights to help reduce unwanted reactions.

Why Semaglutide Can Trigger Heart Palpitations

Semaglutide activates GLP-1 receptors throughout the body, including in heart tissue and blood vessels. This activation causes a cascade of effects: blood vessel dilation, changes in heart rate variability, and shifts in electrolyte balance. These physiological changes are usually mild and resolve within days or weeks as your body adapts.

Rapid dose increases are a leading cause of palpitations in semaglutide users. When the dose jumps quickly, your cardiovascular system experiences a sudden flood of GLP-1 signaling, which can outpace your body's adaptation capacity. Starting low and titrating slowly—a strategy PlexusDx emphasizes—gives your heart time to adjust to new hormone levels.

Dehydration compounds the risk. GLP-1 medications slow gastric emptying, and patients often consume less food and fluid during early treatment. Dehydration thickens blood, reducing its volume and forcing your heart to work harder to maintain circulation. This mechanical stress can trigger palpitations even in patients with no baseline heart disease.

Distinguishing Normal Palpitations from Dangerous Symptoms

Mild palpitations—a flutter in your chest lasting seconds, or a brief sense of your heart racing—are common in the first month of semaglutide and often resolve without intervention. These episodes typically occur at rest, don't cause dizziness, and are not accompanied by chest pain or shortness of breath. They reflect your body's adjustment to a new metabolic state.

Red flags that demand immediate medical attention include chest pain, persistent shortness of breath, fainting, severe dizziness, or palpitations lasting more than a few minutes. These symptoms may indicate arrhythmia, heart strain, or an underlying cardiac condition unmasked by medication. Do not wait to contact emergency services or your doctor if you experience any of these.

Your medical history matters. Patients with pre-existing hypertension, diabetes, or structural heart disease are at higher risk for serious palpitations and should be monitored more closely. PlexusDx collects detailed cardiovascular history before prescribing to identify high-risk candidates who may benefit from a different GLP-1 approach or closer clinical oversight.

Practical Steps to Reduce Palpitations on Semaglutide

Hydration is non-negotiable. Drink at least 8–10 glasses of water daily, more if you exercise or live in a hot climate. Electrolyte replacement—through low-sugar electrolyte drinks, broth, or salt-preserved foods—helps maintain sodium and potassium levels needed for normal heart rhythm. Many patients find palpitations disappear once they prioritize fluid intake.

Slow your dose escalation. PlexusDx does not use aggressive dose ladders; instead, your provider adjusts your dose based on your response and tolerability. If palpitations emerge, staying at your current dose for an extra week or two allows your body to acclimate. There is no race to reach a target dose—steady, tolerable progress prevents complications.

Monitor caffeine and stimulants. Caffeine, nicotine, and some decongestants can irritate heart tissue and trigger palpitations when combined with GLP-1 therapy. Reducing or eliminating these substances during your first month on semaglutide may prevent palpitations entirely. Once you've stabilized on your dose, you can cautiously reintroduce small amounts if desired.

How Personalized Genetic Testing Predicts Palpitation Risk

PlexusDx Precision Peptide Genetic Test identifies inherited variations in GLP-1 receptor (GLP1R rs6923761) and MC4R genes that influence how your cardiovascular system responds to semaglutide. Some genetic profiles show heightened sensitivity to GLP-1 signaling, predisposing these patients to palpitations. Knowing your genetic risk before treatment begins allows your provider to start at a lower microdose or choose an alternative compound.

The test maps 14 metabolic and cardiovascular pathways across 49 peptides and 150+ genetic insights. Results guide dose selection and help determine whether you'd benefit from PlexusDx's Microdose GLP-1 Protocol ($129/mo), which uses smaller starting doses for genetically sensitive patients, or whether tirzepatide—a dual GIP and GLP-1 agonist—might produce fewer palpitations due to its different receptor binding profile.

Testing costs $99 as an add-on after your first month of treatment. This timing allows your provider to observe how you respond clinically before test results arrive, then adjust your regimen based on genetic insights. For patients experiencing palpitations, genetic data often explains the cause and suggests which medication or dose adjustment will work best.

When to Switch Medications or Adjust Your Treatment Plan

If palpitations persist despite hydration, slow dose increases, and lifestyle changes after 3–4 weeks, your provider may recommend a lower microdose, a pause in treatment, or a switch to a different GLP-1 compound. PlexusDx offers multiple options: oral semaglutide ($249/mo), tirzepatide injection ($249/mo), or the Microdose GLP-1 Protocol ($129/mo) if you have genetic predisposition to cardiovascular sensitivity.

Some patients tolerate tirzepatide better than semaglutide because tirzepatide activates both GLP-1 and GIP receptors differently, producing a more gradual cardiovascular effect. PlexusDx compounded tirzepatide injection starts at $249/mo, with your dose adjusting based on response—not a preset schedule. Your provider will work with you to find the medication and dose that balances weight loss efficacy with heart-rhythm safety.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Are heart palpitations from semaglutide dangerous?

Most palpitations on semaglutide are harmless and resolve within weeks as your body adapts. However, chest pain, fainting, or severe shortness of breath warrant immediate medical evaluation. PlexusDx providers screen for cardiac risk factors before treatment and monitor your symptoms closely.

How long do palpitations last when starting semaglutide?

Mild palpitations typically fade within 2–4 weeks once your dose stabilizes and you maintain good hydration. Slower dose escalation—an approach PlexusDx emphasizes—shortens the duration and severity of symptoms in most patients.

Can I stop semaglutide if palpitations develop?

Stopping abruptly is not advisable, as rapid hormone changes can cause rebound effects. Instead, contact your PlexusDx provider to adjust your dose, switch medications, or explore the Microdose GLP-1 Protocol ($129/mo), which uses lower starting doses for sensitive patients.

What is the PlexusDx Precision Peptide Genetic Test?

It is a peptide-pathway genetic test (not pharmacogenomic) that identifies variants in your GLP-1 receptor, GIP receptor, and appetite-regulation genes. Results predict your cardiovascular response to semaglutide and guide dosing decisions. The test costs $99 and can be added after your first month of treatment.

Is compounded semaglutide from PlexusDx as safe as Ozempic?

PlexusDx semaglutide is manufactured by licensed 503A compounding pharmacies under strict quality controls. While not FDA-approved (unlike Ozempic), compounded semaglutide is clinically equivalent and often better tolerated because PlexusDx offers flexible, personalized dosing rather than fixed dose pens. Compounded injection starts at $149/mo, with no your dose may need to go up - your price won't rises.

Does PlexusDx serve all 50 states?

Yes. PlexusDx delivers compounded semaglutide, tirzepatide, and GLP-Squared formulations to all 50 states without insurance or a membership fee. HSA and FSA accounts can be used for payment.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves